LSD Redesign Unlocks Brain Repair 100x Stronger – No Hallucinations, Game-Changer for Mental Health!

admin3 hours ago

0 5 1 minute read

Researchers at the University of California, Davis (UC Davis), led by David E. Olson (director of the Institute for Psychedelics and Neurotherapeutics), have developed JRT—a non-hallucinogenic analogue of LSD—through a remarkably simple molecular tweak: transposing just two atoms (a carbon and a nitrogen in the ergoline core). Olson compares this change to a “tire rotation”—the molecule retains a near-identical shape and weight to LSD but dramatically alters its pharmacology.Published in Proceedings of the National Academy of Sciences (PNAS) in April 2025, the study shows JRT acts as a potent psychoplastogen: it selectively binds to serotonin 5-HT2A receptors (partial agonist, with improved selectivity over LSD), promoting robust neuroplasticity without triggering hallucinations. Key effects include:

Stimulating growth of dendritic spines and synapses in the prefrontal cortex (e.g., 46% increase in spine density and 18% in synapse density in mouse models).
Promoting dendritic arbor complexity and spinogenesis in cultured neurons and in vivo.
Rescuing stress-induced (chronic corticosterone) synaptic loss in the medial prefrontal cortex.
Producing strong antidepressant-like effects and improvements in behaviors/models relevant to depression and schizophrenia (negative/cognitive symptoms), without exacerbating psychosis-related behaviors or gene expression.

Unlike classic psychedelics (which risk inducing psychosis in vulnerable populations like schizophrenia patients), JRT shows lower hallucinogenic potential (e.g., no head-twitch response in mice, a proxy for hallucinations) due to disrupted key hydrogen bonding at the receptor and shorter binding duration.While preclinical data is highly promising—highlighting JRT’s potential for treating conditions involving synaptic atrophy (depression, schizophrenia, neurodegeneration like Alzheimer’s/Parkinson’s, traumatic brain injury, stroke)—human clinical trials are still needed to confirm safety, efficacy, and dosing. Olson’s team (including collaborators at Delix Therapeutics, which licensed related tech) continues optimizing analogues and testing in additional disease models.This breakthrough exemplifies the shift toward “non-hallucinogenic psychedelics” or psychoplastogens: harnessing psychedelics’ brain-rewiring power safely, without the trip. For visuals of JRT’s effects (e.g., neuron images showing spine growth or molecular structures), scientific illustrations from the paper depict dramatic increases in dendritic complexity and spines compared to controls or traditional antipsychotics like clozapine.The work builds on Olson’s broader research into psychoplastogens and could pave the way for next-generation treatments that physically repair brain architecture rather than just managing symptoms.